https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39356 Wed 31 Aug 2022 15:20:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43678 Framework to Assess the Impact from Translational health research (FAIT) to Lessons from the Best to Better the Rest (LFTB), (2) report on impacts from LFTB and (3) assess the feasibility and outcomes from a retrospective application of FAIT. Setting: Three Indigenous primary healthcare (PHC) centres in the Northern Territory, Australia; project coordinating centre distributed between Townsville, Darwin and Cairns and the broader LFTB learning community across Australia. Participants: LFTB research team and one representative from each PHC centre. Primary and secondary outcome measures: Impact reported as (1) quantitative metrics within domains of benefit using a modified Payback Framework, (2) a cost-consequence analysis given a return on investment was not appropriate and (3) a narrative incorporating qualitative evidence of impact. Data were gathered through in-depth stakeholder interviews and a review of project documentation, outputs and relevant websites. Results: LFTB contributed to knowledge advancement in Indigenous PHC service delivery; enhanced existing capacity of health centre staff, researchers and health service users; enhanced supportive networks for quality improvement; and used a strengths-based approach highly valued by health centres. LFTB also leveraged between $A1.4 and $A1.6 million for the subsequent Leveraging Effective Ambulatory Practice (LEAP) Project to apply LFTB learnings to resource development and creation of a learning community to empower striving PHC centres. Conclusion: Retrospective application of FAIT to LFTB, although not ideal, was feasible. Prospective application would have allowed Indigenous community perspectives to be included. Greater appreciation of the full benefit of LFTB including a measure of return on investment will be possible when LEAP is complete. Future assessments of impact need to account for the limitations of fully capturing impact when intermediate/final impacts have not yet been realised and captured.]]> Wed 28 Sep 2022 14:52:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51411 Wed 28 Feb 2024 15:41:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52580 Wed 28 Feb 2024 15:38:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53245 Wed 28 Feb 2024 15:32:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52331 Wed 28 Feb 2024 15:00:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52044 Wed 27 Sep 2023 10:07:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45029 Wed 26 Oct 2022 15:43:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45064 Wed 26 Oct 2022 11:42:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36899 Wed 24 Nov 2021 15:53:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35468 0.05). HbA1c was significantly higher in children offered food in a grazing pattern compared with those offered regular meals (mean 61 mmol/mol vs 43 mmol/mol (7.7% vs 6.1%), p=0.01). Conclusions: Dietary quality is a concern in young children with T1D with excessive saturated fat and inadequate vegetable intake. Our results suggest that young children meeting glycemic targets give insulin before meals and follow a routine eating pattern.]]> Wed 24 Nov 2021 15:51:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37320 Wed 24 Nov 2021 15:51:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34855 Wed 24 May 2023 12:20:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55179 Wed 24 Apr 2024 09:34:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54396 Wed 21 Feb 2024 15:34:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52293 Wed 17 Apr 2024 14:31:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43181 40 000 participants. Included studies consistently reported an increased risk associated with greater numbers of intraindividual risk factors or unhealthy behaviours and the opposite for healthy or protective behaviours. A meta-analysis of studies with dementia outcomes resulted in a pooled relative risk for dementia of 1.20 (95% CI 1.04 to 1.39) for one risk factor, 1.65 (95% CI 1.40 to 1.94) for two and 2.21 (95% CI 1.78 to 2.73) for three or more, relative to no risk factors. Limitations include dependence on published results and variations in study outcome, cognitive assessment, length of follow-up and definition of risk factor exposure. Conclusions The strength of the reported associations, the consistency across studies and the suggestion of a dose response supports a need to keep modifiable risk factor exposure to a minimum and to avoid exposure to additional modifiable risks. Further research is needed to establish whether particular combinations of risk factors confer greater risk than others.]]> Wed 14 Sep 2022 08:23:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51650 Wed 13 Sep 2023 09:53:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45011 Wed 13 Mar 2024 09:23:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53187 Wed 13 Mar 2024 08:48:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36126 Wed 12 Feb 2020 16:22:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36125 Wed 12 Feb 2020 16:01:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52469 Wed 11 Oct 2023 20:44:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53721 Wed 10 Jan 2024 11:18:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37441 Wed 09 Mar 2022 15:59:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49874 Wed 07 Jun 2023 18:21:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43060 Wed 07 Feb 2024 14:49:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36127 50%) is detected, DerSimonian & Laird inverse-variance random effects model. Pooled estimates and 95% CIs will be calculated for overall participant retention rates and for intervention and control trial arms separately. Associations between participant retention and participant, environmental, researcher and study factors will be assessed via subgroup analyses and, where sufficient data are obtained, meta-regression. Ethics and dissemination: This study does not require ethical approval. The findings of this review will be disseminated via publication in a peer-reviewed open access medical journal and presentations at international scientific meetings.]]> Wed 02 Mar 2022 14:25:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36725 Tue 30 Aug 2022 12:10:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51269 Tue 29 Aug 2023 15:41:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53479 Tue 28 Nov 2023 16:00:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41119 Tue 26 Jul 2022 13:42:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39051 Tue 21 Mar 2023 17:43:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44636 Tue 18 Oct 2022 15:02:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41928 Tue 16 Aug 2022 14:47:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41961 Tue 16 Aug 2022 14:45:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55144 Tue 16 Apr 2024 09:45:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48293 Tue 14 Mar 2023 11:26:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47985 Tue 14 Feb 2023 14:22:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43062 Tue 13 Sep 2022 08:32:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34415 Tue 03 Sep 2019 18:11:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33894 Tue 03 Sep 2019 18:02:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33661 Tue 03 Sep 2019 18:01:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38102 Tue 03 Aug 2021 19:06:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41338 Tue 02 Aug 2022 09:16:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41335 Tue 02 Aug 2022 09:09:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33364 Thu 28 Oct 2021 13:03:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45384 Thu 27 Oct 2022 16:12:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45367 Thu 27 Oct 2022 15:37:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45230 Thu 27 Oct 2022 12:26:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36706 Sherlock (UK, BBC, 2010-), Homeland (USA, Showtime, 2011-), Perception (USA, TNT, 2012-2015), Hannibal (USA, NBC, 2013-2015) and Black Box (USA, ABC, 2014). Theoretically, this paper draws on Sami Schalk's formulation of the 'superpowered supercrip narrative', which refers to the 'representation of a character who has abilities or «powers» that operate in direct relationship with or contrast to their disability'. This paper is also indebted to Davi A Johnson's 'Managing Mr. Monk' (2008) for its discussion of mental illness as attaining 'social value' through becoming a resource with economic and ethical value, as do the conditions of the fictional characters explored in this article. Schalk's work on disability is here expanded to a more specific discussion of mental illness on television, while Johnson's work is updated to discuss whether the newer characterisations reflect the same rhetorical positioning as Monk (USA, USA Network, 2002-2009), one of the earliest texts celebrated for featuring a lead, sympathetic character clearly and explicitly identified with a mental health condition. Of the five lead characters examined here, three are figured as responsible for their symptoms because they have chosen not to take medication or withdraw from their medication. It is concurrently presented that if they do take medication, it dampens their abilities to perform valuable work in the community, thus removing their use value within the world of the series.]]> Thu 25 Jun 2020 15:14:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53382 Thu 23 Nov 2023 12:54:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51873 Thu 21 Sep 2023 10:23:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38648 Thu 18 Aug 2022 14:52:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48407 Thu 16 Mar 2023 14:03:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48041 Thu 16 Feb 2023 13:59:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36434 4 lobes), normal (2-4 lobes) and banded (1 lobe) neutrophils and enumerated. Results: Neutrophils from each subset were identified in all participants. Numbers of hypersegmented neutrophils were elevated in participants with airway disease compared with healthy controls (p<0.001). Both the number and the proportion of hypersegmented neutrophils were highest in COPD participants (median (Q1-Q3) of 1073.6 (258.8-2742) x 10 2/mL and 24.5 (14.0-46.5)%, respectively). An increased proportion of hypersegmented neutrophils in airway disease participants was significantly associated with lower forced expiratory volume in 1 s/forced vital capacity per cent (Spearman's r=-0.322, p=0.004). Conclusion: Neutrophil heterogeneity is common in BL and is associated with more severe airflow obstruction in adults with airway disease. Further work is required to elucidate the functional consequences of hypersegmented neutrophils in the pathogenesis of disease.]]> Thu 13 Jan 2022 10:29:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38626 Thu 09 Dec 2021 14:48:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55039 Thu 04 Apr 2024 13:44:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52934 Thu 02 Nov 2023 15:16:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52851 30%. For each group, an age–period– cohort model or generalised linear model with cigarette smoking exposure as a covariate was selected based on the model fit statistics and validation using observed data. The smoking-attributable fraction (SAF) was calculated for each smoking-related cancer using Australian smoking prevalence data and published relative risks. Results: Despite the decreasing mortality rates projected for the period 2015–2019 to 2040–2044 for both men and women, the overall number of smoking-related cancer deaths is estimated to increase by 28.7% for men and 35.8% for women: from 138 707 (77 839 men and 60 868 women) in 2015–2019 to 182 819 (100 153 men and 82 666 women) in 2040–2044. Over the period 2020–2044, there will be 254 583 cancer deaths (173 943 men and 80 640 women) directly attributable to smoking, with lung, larynx, oesophagus and oral (comprising lip, oral cavity and pharynx) cancers having the largest SAFs. Interpretation: Cigarette smoking will cause over 250 000 cancer deaths in Australia from 2020 to 2044. Continued efforts in tobacco control remain a public health priority, even in countries where smoking prevalence has substantially declined.]]> Mon 30 Oct 2023 09:54:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38392 Mon 29 Jan 2024 17:47:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54035 Mon 29 Jan 2024 13:39:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51980 Mon 25 Sep 2023 12:09:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52698 Mon 23 Oct 2023 14:05:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42358 Mon 22 Aug 2022 14:01:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46019 Mon 21 Nov 2022 08:45:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51790 Mon 18 Sep 2023 15:19:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35059 Mon 17 Jun 2019 11:20:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50964 Mon 14 Aug 2023 15:18:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43053 Mon 12 Sep 2022 15:20:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51588 Mon 11 Sep 2023 15:25:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51567 Mon 11 Sep 2023 14:22:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52299 Mon 09 Oct 2023 10:19:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37123 Mon 06 Mar 2023 16:12:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42851 Mon 05 Sep 2022 15:40:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51410 Mon 04 Sep 2023 14:50:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53538 Mon 04 Dec 2023 15:44:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35027 9 g/day. Results: Median daily sodium excretion was equivalent to 6.3 g salt/day (range 1–43 g/day); 35% had urinary sodium excretion values within the desirable range (<5 g salt/day), 37% had high values (5–9 g salt/day) and 28% had very high values (>9 g salt/day). Median UIC was 130 µg/L (IQR=58–202), indicating population iodine sufficiency (≥100 µg/L). Both UIC and UIE differed across salt intake categories (p<0.001) and were positively correlated with estimated salt intake (r=0.166 and 0.552, respectively; both p<0.001). Participants with salt intakes of <5 g/day were not meeting the Estimated Average Requirement for iodine intake (95 µg/day). Conclusions: In a nationally representative sample of South African adults, the association between indicators of population iodine status (UIC and UIE) and salt intake, estimated using 24-hour urinary sodium excretion, indicate that low salt intakes may compromise adequacy of iodine intakes in a country with mandatory iodisation of table salt. The iodine status of populations undergoing salt reduction strategies needs to be closely monitored to prevent re-emergence of iodine deficiency.]]> Mon 03 Jun 2019 14:03:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45146 Fri 28 Oct 2022 11:10:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42591 Fri 26 Aug 2022 09:08:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35691 Fri 25 Oct 2019 12:03:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51884 Fri 22 Sep 2023 09:08:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52654 Fri 20 Oct 2023 08:55:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35711 Fri 19 Aug 2022 12:27:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38686 Fri 19 Aug 2022 10:18:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53104 Fri 17 Nov 2023 11:38:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53184 18 years) with or without a history of LBP recruited in April 2019 with quotas for country, age and gender. Primary and secondary outcome measures: Self-reported understanding of 14 terms (annular fissure, disc bulge, disc degeneration, disc extrusion, disc height loss, disc protrusion, disc signal loss, facet joint degeneration, high intensity zone, mild canal stenosis, Modic changes, nerve root contact, spondylolisthesis and spondylosis) commonly found in lumbar spine imaging reports. For each term, we also elicited worry about its seriousness, and whether its presence would indicate pain persistence and prompt fear of movement. Results: From 774 responses, we included 677 (87.5%) with complete and valid responses. 577 (85%) participants had a current or past history of LBP of whom 251 (44%) had received lumbar spine imaging. Self-reported understanding of all terms was poor. At best, 235 (35%) reported understanding the term € disc degeneration', while only 71 (10.5%) reported understanding the term € Modic changes'. For all terms, a moderate to large proportion of participants (range 59%-71%), considered they indicated a serious back problem, that pain might persist (range 52%-71%) and they would be fearful of movement (range 42%-57%). Conclusion: Common and usually non-serious terms in lumbar spine imaging reports are poorly understood by the general population and may contribute to the burden of LBP. Trial registration number: ACTRN12619000545167.]]> Fri 17 Nov 2023 11:26:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43404 Fri 16 Sep 2022 10:12:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37977 Fri 16 Jul 2021 11:21:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51721 Fri 15 Sep 2023 17:53:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51684 Fri 15 Sep 2023 09:37:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40026 2=0%), US$3857.34 (95% CI US$−7293.93 to US$15 008.61, I²=45.9%), US$37 577.74 (95% CI US$−649.02 to US$75 804.50, I²=92.4%) and US$14 062.42 (95% CI US$8168.69 to US$19 956.15, I²=86.4%), respectively. GLP1s were statistically significantly cost-effective compared with insulins, but not compared with DPP4i, sulfonylureas, and TZDs. Among GLP1s, liraglutide was more cost-effective compared with lixisenatide, but not compared with exenatide, with corresponding pooled INBs of US$4555.09 (95% CI US$3992.60 to US$5117.59, I²=0) and US$728.46 (95% CI US$−1436.14 to US$2893.07, I²=0), respectively. Conclusion: GLP1 agonists are a cost-effective choice compared with insulins, but not compared with DPP4i, sulfonylureas and TZDs. PROSPERO registration number: CRD42018105193.]]> Fri 15 Jul 2022 10:11:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36131 Fri 14 Feb 2020 11:25:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49106 Fri 05 May 2023 11:32:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50749 Fri 04 Aug 2023 10:45:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52952 Fri 03 Nov 2023 11:05:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37891 Fri 03 Dec 2021 10:34:20 AEDT ]]>